Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 28-week, Prospective, Single-arm, Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL in Combination With Prandial Rapid-acting Insulin Analogue in Patients With Type 1 Diabetes Previously Uncontrolled on Twice-daily Basal Insulin as Part of Basal-bolus Therapy

NCT03406000 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03406000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03406000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 28-week, Prospective, Single-arm, Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL in Combination With Prandial Rapid-acting Insulin Analogue in Patients With Type 1 Diabetes Previously Uncontrolled on Twice-daily Basal Insulin as Part of Basal-bolus Therapy
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
January 22, 2018
Completion date
February 4, 2019
Enrollment
170 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

type i diabetes mellitus